BACKGROUND AND OBJECTIVE: The optimal time for changing failing antiretroviral therapy (ART) is not known. It involves balancing the risk of exhausting future treatment options against the risk of developing increased drug resistance. The frequency with which new drug-resistance mutations (DRM) developed and their potential consequences in patients continuing unchanged treatment despite persistent viremia were assessed. DESIGN: A retrospective study of consecutive sequence samples from 106 patients at one institution with viral load (VL) of more than 400 copies/ml, with no change in ART for more than 2 months despite virologic failure. METHODS: Two consecutive pol sequences, CD4 cell counts and VL were analyzed to quantify the development of new DRM and to identify changes in immunologic and virologic parameters. Genotypic susceptibility scores (GSS) and viral drug susceptibilities were calculated by a computer program (HIVDB). Poisson log-linear regression models were used to predict the expected number of mutations at the second time point. RESULTS: : After a median of 14 months of continued ART, 75% (80 of 106) of patients acquired new DRM and were assigned a significantly lower GSS, potentially limiting the success of future ART. The development of new DRM was proportional to the time between the two sequences and inversely proportional to the number of DRM in the first sequence. However, the development of DRM was not associated with significant changes in CD4 or VL counts. CONCLUSIONS: Despite stable levels of CD4 and VL over time, maintaining a failing therapeutic regimen increases drug resistance and may limit future treatment options.
BACKGROUND AND OBJECTIVE: The optimal time for changing failing antiretroviral therapy (ART) is not known. It involves balancing the risk of exhausting future treatment options against the risk of developing increased drug resistance. The frequency with which new drug-resistance mutations (DRM) developed and their potential consequences in patients continuing unchanged treatment despite persistent viremia were assessed. DESIGN: A retrospective study of consecutive sequence samples from 106 patients at one institution with viral load (VL) of more than 400 copies/ml, with no change in ART for more than 2 months despite virologic failure. METHODS: Two consecutive pol sequences, CD4 cell counts and VL were analyzed to quantify the development of new DRM and to identify changes in immunologic and virologic parameters. Genotypic susceptibility scores (GSS) and viral drug susceptibilities were calculated by a computer program (HIVDB). Poisson log-linear regression models were used to predict the expected number of mutations at the second time point. RESULTS: : After a median of 14 months of continued ART, 75% (80 of 106) of patients acquired new DRM and were assigned a significantly lower GSS, potentially limiting the success of future ART. The development of new DRM was proportional to the time between the two sequences and inversely proportional to the number of DRM in the first sequence. However, the development of DRM was not associated with significant changes in CD4 or VL counts. CONCLUSIONS: Despite stable levels of CD4 and VL over time, maintaining a failing therapeutic regimen increases drug resistance and may limit future treatment options.
Authors: Steven G Deeks; Rebecca Hoh; Robert M Grant; Terri Wrin; Jason D Barbour; Amy Narvaez; Denise Cesar; Ken Abe; Mary Beth Hanley; Nicholas S Hellmann; Christos J Petropoulos; Joseph M McCune; Marc K Hellerstein Journal: J Infect Dis Date: 2002-01-17 Impact factor: 5.226
Authors: A R Zolopa; R W Shafer; A Warford; J G Montoya; P Hsu; D Katzenstein; T C Merigan; B Efron Journal: Ann Intern Med Date: 1999-12-07 Impact factor: 25.391
Authors: J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan Journal: AIDS Date: 2000-06-16 Impact factor: 4.177
Authors: J E Fitzgibbon; S Gaur; S M Walsman; M Janahi; P Whitley-Williams; J F John Journal: AIDS Res Hum Retroviruses Date: 2001-09-20 Impact factor: 2.205
Authors: Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Jason D Barbour; Terri Wrin; Robert M Grant; Jeffrey N Martin; Mark R Segal; Christos J Petropoulos; Steven G Deeks Journal: J Virol Date: 2002-11 Impact factor: 5.103
Authors: Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor Journal: Clin Infect Dis Date: 2012-04-26 Impact factor: 9.079
Authors: Jeffrey I Boucher; Troy W Whitfield; Ann Dauphin; Gily Nachum; Carl Hollins; Konstantin B Zeldovich; Ronald Swanstrom; Celia A Schiffer; Jeremy Luban; Daniel N A Bolon Journal: Mol Biol Evol Date: 2019-04-01 Impact factor: 16.240
Authors: Y Yazdanpanah; M Vray; J Meynard; E Losina; M C Weinstein; L Morand-Joubert; S J Goldie; H E Hsu; R P Walensky; C Dalban; P E Sax; P M Girard; K A Freedberg Journal: HIV Med Date: 2007-10 Impact factor: 3.180
Authors: Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien Journal: J Acquir Immune Defic Syndr Date: 2006-12-15 Impact factor: 3.731